Product Images Onyda Xr

This text is too short and does not provide enough context to generate a description.*

This description provides a brief overview of a time-based study involving the administration of different medications at specific time points. One medication, ONYDA XR, was given fed at a dosage of 0.2 mg at the beginning of the study. Another medication, Clonidine HCI extended-release tablets, was administered fasted at dosages of 0.1 mg at 0 and 12 hours. The time points are listed in terms of hours along with the medication administrations.*

This text provides important instructions and information about the medication ONYDA XR (clonidine hydrochloride) extended-release oral suspension. It includes details on recommended dosage, storage conditions, composition, expiration date, and manufacturer information. It emphasizes the need to shake the product before use, store it at a specific temperature range, and discard it after a certain period. The text also mentions that it is a physician sample and should not be sold. Additionally, there are details about tamper evident features to ensure product integrity. The text also provides an NDC code for identification.*

This document provides important information about ONYDA XR, an extended-release oral suspension containing clonidine hydrochloride. It is intended for oral use only and should not be substituted with other clonidine products based on milligram-per-milligram comparison. The recommended dosage can be found in the Prescribing Information. It is essential to keep this medication out of children's reach. Each mL of the suspension contains 0.1 mg of clonidine hydrochloride, equivalent to 0.08 mg of clonidine base. The product should be stored in the original bottle at 20°C to 25°C, with excursions to 15°C to 30°C permitted, protected from light. It is necessary to shake the bottle gently before each use for at least 10 seconds to avoid foaming. Instructions for use are provided, and any unused product should be discarded within 60 days of opening the bottle. If the seal is broken, the product should not be used to ensure safety. Manufactured by Tris Pharma, Inc., ONYDA XR is designed for physician samples and is not for sale.*

This text provides important information on the proper usage and storage of an extended-release clonidine hydrochloride suspension. It includes instructions on shaking the product before use, recommended dosage, storage conditions, and tamper-evident precautions. The text also specifies the expiration date after opening, manufacturer information, and a caution to keep the product away from children.*

This is a product label for ONYDA™ XR, an extended-release oral suspension containing clonidine hydrochloride. The recommended dosage and precautions are mentioned, emphasizing not to substitute for other clonidine products. It provides details on storage, usage, and expiration of the product. The label also includes information about the manufacturer, Tris Pharma Inc., and the various components included in the packaging.*

This document appears to show the estimated proportion of patients experiencing treatment failure over a period of time in a study involving Clonidine Hydrochloride Extended-Release Tablets and Placebo. The graph displays the data points for each treatment group, with days from randomization to treatment failure on the x-axis and the proportion of patients on the y-axis. The information suggests a comparative analysis of treatment effectiveness between the two groups.*

This text appears to be describing parts of an oral dosing syringe and bottle adapter. It mentions the plunger and a white end tip of the plunger. This suggests that the syringe is likely used for measuring and administering liquid medication.*

This text mentions a "bottle adapter" with a "rigid end" designed to fit into a "bottle neck". This suggests that the adapter is likely a tool or attachment used to modify or enhance the functionality of bottles.*